Spheramine is being developed by Titan in collaboration with Bayer Schering Pharma. Results from the study are expected to be available in the third quarter of 2008.
According to the company, results from a previous open label study of Spheramine in six patients demonstrated an average 48% improvement in motor function over baseline at one year after treatment. Data from this study also demonstrated significant improvement in quality of life for all patients treated, with no significant adverse events.